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Abstract  34 
Ochratoxin A (OTA) is a mycotoxin produced by Aspergillus and Penicillium species with 35 
immunosuppressive, teratogenic and carcinogenic properties. It has been determined that wine is 36 
the second source of OTA (10% of total OTA intake) in the European diet, and that its presence, 37 
even in small doses, can be a problem for long-term toxicity. In this paper we evaluated the 38 
bioaccessibility of OTA in a spiked red wine, in fasting human conditions, using an in vitro 39 
dynamic digestion model that includes a continuous-flow dialysis system to simulate the 40 
intestinal passage. To our knowledge, this is the first report on bioaccessibility of OTA in wine. 41 
A liquid-liquid method was used for the extraction of the OTA and ochratoxin alpha (OTα) from 42 
the gastrointestinal juices, and the extracts were analyzed by HPLC-FD. The bioaccessibility of 43 
OTA from the spiked red wine (1.0, 2.0 and 4 µg/L) was high in the gastric compartment 44 
(102.8%, 128.3% and 122.3%, respectively), whereas in the simulated intestine it did not exceed 45 
the 26%, and the OTA that crossed the dialysis membrane was very low (< 3.3 %). The amount 46 
of OTα in gastric chyme ranged from 5.1-19.1% of the spiked OTA, whereas in the intestinal 47 
compartment it did not exceed the 5%. As conclusion, in the in vitro system assayed, OTA 48 
showed a high bioaccessibility in the simulated stomach, but it decreased after the intestinal 49 
digestion and the passage through the dialysis membrane.  50 
 51 
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1. Introduction 78 
 79 
Ochratoxin A (OTA) is a toxic secondary metabolite naturally produced by some fungal species 80 
belonging to the Aspergillus and Penicillium genera. OTA is a potent nephrotoxin (IARC 2B 81 
group) that also exhibits immunosuppressive, teratogenic, and carcinogenic properties. OTA can 82 
be found in different raw materials (such as cereals and fruits) and foodstuffs, such as grapes and 83 
wine (IARC, 1993). Several studies have reported that the OTA amount in wine can be reduced 84 
but not fully degraded or extracted during the main stages of wine making, either in the 85 
fermentation process (Cecchini et al., 2006; Esti et al., 2012), wine ageing (Anli et al., 2011), or 86 
through physical treatments, e.g., wine clarification and decontamination with adsorbents 87 
(Castellari et al., 2001; Var et al., 2008). 88 
 89 
Due to the adverse effects that OTA can have on health, the Commission Regulation 1881/2006 90 
sets a maximum level of 2 μg of OTA/L for wine and 10 mg of OTA/kg for dried vine fruit 91 
(currants, raisins, and sultanas) (EC, 2006a). Although OTA is usually detected in wine at levels 92 
below 1 μg/L, concentrations exceeding the legal limits are found with frequency (EC, 2002), 93 
which is worrisome considering that wine is the second most important source of OTA (13-10% 94 
of the total intake) in the European diet, after cereals (EC, 2002) and that wines are the second 95 
most consumed alcoholic drink after beer (WHO, 2013). 96 
 97 
It is known that OTA exposure is mostly by ingestion, however, a known intake of mycotoxins 98 
through food does not always reflect the amount of toxin that is able to cross the intestinal 99 
membrane. Some in vitro models have been developed to determine the amount of contaminant 100 
released (bioaccessible fraction) from food during the gastrointestinal passage. Release of the 101 
toxin from food, in the gastrointestinal tract, is a prerequisite for uptake (and bioavailability) in 102 
the body. The bioaccessible fraction is defined as the amount of free contaminant that may 103 
become available for absorption, since it has been released from the matrix and solubilized in the 104 
gastrointestinal fluid (Versantvoort et al., 2004). On the other hand, ochratoxin alpha (OTα) is a 105 
derivative from OTA formed in the gastrointestinal tract when carboxypeptidase A and 106 
chymotrypsin break inside on the peptide bond and carboxyl-end, respectively, of OTA 107 
(Kumagai and Aibara, 1982). 108 
 109 
To date, no bioaccessibility studies of OTA have been developed in wine, a beverage that can be 110 
usually consumed during long periods of adult life. The aim of this study was to estimate the 111 
bioaccessibility of OTA in spiked red wine through a dynamic in vitro gastrointestinal model 112 
simulating the digestion process, as well as the formation of OTα in the gastrointestinal juice.  113 
 114 
2. Materials and methods 115 
2.1. Chemicals, reagents, and equipment 116 
 117 
Ochratoxin A (OTA) (CAS: 303-47-9) (purity 98%) was supplied by Sigma-Aldrich (St. Louis, 118 
MO, USA), whereas ochratoxin alpha (OTα) (CAS: 16281-39-3) was from Romer Labs 119 
Diagnostic (Tulln, Austria). All salts used to prepare the gastrointestinal solutions and the 120 
hydrochloric acid (HCl, 37%) were supplied by Panreac, Chemical S.A. (Barcelona, Spain) or 121 
Fisher Bioreagents (Fair Lawn, NJ). Orthophosphoric acid and sodium sulfide were from 122 
Scharlau Chemical S.A. (Barcelona, Spain). Organic solvents and HPLC grade reagents were 123 
from Fisher Scientific (Leicestershire, UK). The simulated digestive system was designed with 124 
an adapted Liebig-West condenser, endfitting fluid connectors, silicone tubing (12 mm diameter) 125 
and dialysis tubing cellulose membrane from Sigma-Aldrich (D9277) with a molecular mass cut-126 
off of 12400 Da and 32.8 mL/m of capacity (10 mm of flat width x 6 mm of diameter). A D-127 
21FT peristaltic pump from Dinko Instruments (Barcelona, Spain) and a thermostat bath 128 
Tectron-bio-100 from J.P. Selecta, S.A. (Barcelona. Spain) were also employed. 129 
 130 
2.2. Wine 131 
 132 
In this study, we used a commercial Spanish red wine made from a Tempranillo grape variety 133 
harvested in 2011 from the Castilla-La Mancha region. The initial OTA and OTα contamination 134 
in this wine was evaluated using the method described by Muñoz et al. (2009). In-house 135 
validation of the method was done at three OTA and OTα contamination levels (1.0, 2.0, and 4.0 136 
μg/L) to determine the recovery of the toxins from the matrix. Recoveries ranged from 92.4 to 137 
100.0% (RSDr 1.30-11.54%) for OTA and 63.7-66.9% (RSDr 15.9-20.1%) for OTα. The amount 138 
of OTA found in this wine, considering the mean recovery of the method, was 0.103 μg/L, 139 
whereas, as expected, no OTα was detected. This amount of OTA was taken into account for 140 
bioaccessibility calculation. 141 
 142 
2.3. In vitro digestion procedure 143 
 144 
The digestion model used was a slightly modified version of the technique developed by Gil- 145 
Izquierdo et al. (2002), including a continuous-flow dialysis system to simulate the intestinal 146 
passage. The model describes a three-step procedure mimicking the digestive process in the 147 
mouth, stomach (gastric digestion), and small intestine (intestinal digestion). The constituents 148 
and concentrations of the simulated saliva, gastric juice, duodenal juice and bile juice employed 149 
were those described in Versantvoort et al. (2005). Digestion assays were carried out with 5 mL 150 
of red wine (spiked at 1.0, 2.0, or 4.0 μg OTA/L, i.e., with 5, 10 and 20 ng OTA) and the gastric 151 
and intestinal mixtures were incubated for 2 h. The intestinal mixture was introduced into the 152 
dialysis tube in a continuous-flow dialysis system simulating the intestine. 153 
The dialysis system was designed with an adapted Liebig-West condenser and end-fitting fluid 154 
connectors. The first chamber contained the dialysis tube, through which the intestinal mixture 155 
flowed during the intestinal digestion step by using a peristaltic pump with a flow rate of 1 156 
mL/min, and a phosphate buffer solution (PBS, pH 7.4) that bathed the dialysis tube. A 157 
temperate water solution was pumped from a bath through a water jacket to keep the system’s 158 
temperature constant at 37 ºC (Figure 1). 159 
Once the gastric and intestinal digestions completed, the fluids (gastric, intestinal, and the 160 
dialysate) were collected and analyzed. The fluids were centrifuged for 10 minutes at 100 rpm at 161 
10 ºC, yielding a supernatant that was analyzed for OTA and OTα content. Overall, for each 162 
spiking level, six parallel experiments were carried out, from which three were interrupted for 163 
analysis after the gastric phase, and the remaining three underwent the intestinal phase before 164 
their analysis. 165 
 166 
2.4. Sample analysis 167 
2.4.1. Liquid-liquid extraction of OTA and OTα from the simulated physiological fluids 168 
 169 
The extraction of OTA and OTα, was done using the method described by Muñoz et al. (2009), 170 
with slight modifications. The gastric chyme was diluted 1:1 with NaHCO3 (1%), and the pH 171 
adjusted to 3 with 6 M H3PO4; the intestinal chyme and dialysis samples were diluted 1:4 in 172 
H3PO4/NaCl (0.5 M:2 M) and the pH was adjusted to 1.6 using 10% NaHCO3 (Zimmerli and 173 
Dick, 1995). The organic phase was recovered and dried under a gentle stream of nitrogen at 40 174 
ºC. Samples were stored at 4 ºC until HPLC analysis. To determine if the physiological fluids 175 
caused chromatographic interference, two digestions free from wine were performed following 176 
the previously described digestion procedure. After the incubation period for each digestion 177 
phase, the juices were extracted directly or previously spiked with OTA and OTα (at 1.0, 2.0, 178 
and 3.0 μg/L), and the toxin was immediately recovered using the described liquid-liquid 179 
extraction method (Figure 2). 180 
 181 
2.4.2. High Performance Liquid Chromatography (HPLC) analysis 182 
 183 
The HPLC analysis of OTA and OTα was done using a Waters 2695 Separations Module 184 
coupled to a Waters 2475 Multi λ fluorescence detector. The integration software used to manage 185 
the chromatographic data was Empower 2 (2006 Waters Corporation, Database Version 186 
6.10.00.00). Retention times were 10 min (OTα) and 27 min (OTA). Figure 2 shows the 187 
chromatograms of the extracted physiological fluids (spiked or unspiked with OTA and OTα) 188 
and a sample of the spiked wine post-digestion. Method performance was evaluated in terms of 189 
linearity, limit of detection, limit of quantification, inter-day repeatability, and recovery rates. 190 
 191 
2.5. Statistical analysis 192 
 193 
Validation to estimate inter-day repeatability was performed; runs were done by triplicate. 194 
Results are shown as the means ± standard deviations. Analysis of variance (ANOVA) was used 195 
to test if there were significant differences (p< 0.05) in the calculated bioccessibility and for the 196 
values of mycotoxin that cross the dialysis membrane, at the various tested OTA concentrations. 197 
 198 
3. Results and discussion 199 
3.1. Method validation for OTA and OTα analysis 200 
 201 
The detection (LOD) and the quantification (LOQ) limits for the two toxins were experimentally 202 
determined from the calibration curve of a set of two-fold serial dilutions of the toxin standards 203 
(from 100 to 0.006 ng/mL), which was linear in the range from 0.012 to 100 ng/mL (r2=0.995). 204 
The LOD and LOQ determined for OTA were 0.012 and 0.036 ng/mL, whereas for OTα these 205 
were 0.024 and 0.072 ng/mL, respectively. The method was repeatable for the two toxins at the 206 
three assayed spiking levels, with a relative standard deviation (RSDr) bellow 5% in most cases. 207 
OTA and OTα recoveries from the dialysis fraction were similar and most times above 80%, but 208 
in the gastric and intestinal fractions recoveries were lower for OTα (62-78%), although the 209 
RSDr percentages were similar to those obtained with OTA (Table 1). OTA recoveries fit the 210 
performance criteria established in the EU Regulation 401/2006 (EC, 2006b) for the official 211 
control in foodstuffs. Although there are no established performance criteria for OTα, all the 212 
recovery percentages were homogeneous at the three spiking levels. The bioaccessibility results 213 
and the amount of mycotoxin that crossed the dialysis membrane were corrected considering the 214 
recovery rates. 215 
 216 
3.2. Bioaccessibility of OTA in wine 217 
The extractable compounds from the used physiological fluids did not interfere with the 218 
chromatographic analysis of OTA (Figure 2). In our study, OTA levels detected in the gastric 219 
chyme were quite high, representing a bioaccessibility of 102.81, 128.26, and 122.25% in each 220 
of the tested contamination levels (Table 2). No significant differences were determined for the 221 
three bioaccessibility values (p<0.05). Our results show that in the tested OTA concentration 222 
range, the food matrix did not affect the bioaccessibility of OTA in the gastric chyme. 223 
 224 
High bioaccessibility levels (86 to 116%) were determined by Versantvoort et al. (2005) in 225 
buckwheat, peanuts, and mixtures of these cereals (4, 11, 51 ng OTA in the digestion model). 226 
Avantaggiato et al. (2007) also described a high bioaccessibility of OTA (88%) from the 227 
stomach to the small intestine, in a corn food at only one contamination level (11 μg OTA/kg). 228 
Our results and the results of studies mentioned above are in line with the in vivo data reported 229 
by Galtier (1978) and Roth et al. (1988), authors that attribute this behaviour to the acidic 230 
properties of OTA (Galtier, 1978; Kumagai and Aibara, 1982). However, Kabak et al. (2009) 231 
reported much lower bioaccessibilities; only 22% was found for buckwheat (24.9 μg OTA/kg) 232 
and 29-32% for infant food (2-13.1 μg OTA/kg), in spiked foods. 233 
 234 
In our study, during intestinal digestion OTA levels decreased, giving bioaccessibilities ranging 235 
from 21 to 26%, while less than 3.3% was detected in the intestinal dialysate (Table 2). Glahn et 236 
al. (1996) and Jovaní et al. (2001) also observed this behaviour, where the compounds that form 237 
complex with proteins, or with mixed bile salt micelles, as OTA, are likely to be less 238 
bioaccessible.  239 
 240 
Results of in vivo experiments showed that OTA could have highly variable bioavailability 241 
values. For example, the highest bioavailability was reported in mouse (92%), followed by pigs 242 
(65.7%), rats (61%), monkeys (57%), rabbits (55.6%), chickens (40%) and fish (1.6%) (Galtier 243 
and Alvinerie, 1981; Hagelberg et al., 1989). Unlike of the in vitro systems, it has to be noted 244 
that in vivo the absorption in proximal jejunum depends of gastric emptying, mechanical 245 
movements and can take place against a concentration gradient and depends on the pH at the 246 
mucosal surface of the jejunum Kumagai, 1988; Kumagai and Aibara, 1982). 247 
 248 
In our case, the bioaccessibility did not depend on initial mycotoxin levels (p<0.05), neither at 249 
the gastric nor at the intestinal phase. However, with other mycotoxins, differences in 250 
bioaccessibility could also be related to the way the matrix (food or feed) is contaminated 251 
(spiked or naturally), and the bioaccessibility model employed for studying the release of 252 
mycotoxins from the matrix. Two in vitro models to study mycotoxin bioaccessibility have been 253 
primarily used by different authors: 1) the RIVM model (Versantvoort et al., 2004) and 2) the 254 
Gil-Izquierdo model (Gil- Izquierdo et al., 2002). A third model, the TIM-1 model, has been 255 
mainly employed in bioaccessibility assays of mycotoxins from cereals or food (Avantaggiato et 256 
al., 2003, 2004, 2007; Zeijdner et al., 2003) in porcine gastrointestinal tract conditions. In-depth 257 
review of the conditions and digestion models was done in our previous study on mycotoxin 258 
bioaccessibility (González-Arias et al., 2013). 259 
 260 
Regarding formation of OTα metabolite, generally low amounts were detected in our in vitro 261 
digestion system. In the gastric chyme, OTα was detected in a range representing 5.1-19.1% of 262 
the initial OTA, and in the small intestine juice 5.1% of the metabolite was detected only in the 263 
digestion of the wine spiked at 4 μg OTA/mL. In the dialysis fraction, OTα was detected but not 264 
quantified because the signal was below LOQ. Our results are in agreement with Madhyasta et 265 
al. (1992); the authors used an in vitro system based on the incubation of OTA with rat digesta, 266 
and found that most OTA hydrolysis to OTα occurs in the presence of digesta from the large 267 
intestine or ceacum, but little hydrolysis was observed in the stomach contents and digesta from 268 
the small intestine, despite the fact that the pancreatic enzymes, including carboxypeptidase A, 269 
are released into the small intestine. Additionally, the biotransformation of OTA into OTα is 270 
probably higher in vivo or in vitro systems involving intestinal cellular systems in comparison to 271 
our in vitro system, where scarcely any biotransformation was seen. In our results, as in the case 272 
of other studies, several additional factors were not taken into account, e,g., the interaction of the 273 
toxin with the intestinal microbiota in the large intestine (mainly anaerobic bacteria) 274 
(Madhyastha et al., 1992), the effect of the toxin´s metabolism during the transport through the 275 
intestinal barrier and liver degradation on the in vivo oral bioavailable OTA (Berger et al., 2003; 276 
Schrickx et al., 2006). 277 
 278 
4. Conclusions 279 
 280 
The present study shows that OTA is mainly released from the wine matrix during gastric 281 
digestion (providing high bioaccessibility at this point). However, most probably the in vivo 282 
bioavailability of this toxin decreases due to a low bioaccessibility, and presumably low 283 
bioavailability, at the small intestine. 284 
 285 
In vitro models are only approximations of what may occur in vivo and the few studies carried 286 
out to determine the bioaccessibility of OTA in different food matrices, naturally or artificially 287 
contaminated, have given inconsistent results. Most in vitro bioaccessibility assays for 288 
mycotoxins have not been carried out for more than two hours of gastric digestion and few 289 
matrices have been used under fasting or fed conditions. Further studies should be conducted to 290 
determine the effect that OTA contamination level, type of contamination (natural vs spiked), 291 
and food matrices exerts on bioaccessibility. Additional data are required to consider these 292 
results representative of what happens in vivo conditions. 293 
 294 
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